Skip to main content

Table 2 Combination scores for eribulin-ifosfamide and eribulin-pazopanib calculated by Synergy finder. Mean of two experiments and SD are included for each algorithm

From: Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?

Cell line Combination ZIP HSA BLISS LOEWE
HT1080 Eribulin + Ifosfamide 7.27 ± 2.41 10.08 ± 1.94 8.22 ± 2.37 4.39 ± 1.29
SK-UT-1 3.74 ± 0.76 7.07 ± 1.26 4.18 ± 0.84 0.7 ± 2.63
SW872 7.49 ± 4.24 8.75 ± 5.07 7.8 ± 4.32 4.48 ± 4.31
LIPODL221 1.31 ± 1.55 6.07 ± 1.33 2,90 ± 0.34 1.99 ± 0.50
93T449 5,19 ± 0.28 7.74 ± 2.48 6.48 ± 2.38 2.55 ± 1.61
LPS224 6,98 ± 0.04 7.77 ± 0.99 7.81 ± 0.44 4.26 ± 0.34
LPS246 2.27 ± 1.15 5.28 ± 0.17 2.68 ± 1.25 1.69 ± 0.32
SK-UT-1 Eribulin + Pazopanib 4.08 ± 4.34 10.25 ± 0.50 5.17 ± 2.49 5.53 ± 1.31
SW872 8.81 ± 1.92 13.97 ± 0.03 9.19 ± 1.41 8.00 ± 0.03
LIPODL221 3.38 ± 2.29 11.07 ± 1.40 3.37 ± 2.24 7.67 ± 1.98
  1. ZIP Zero Interaction Potency, HSA Highest Single Agent, LOEWE Loewe additivity model, BLISS Bliss model